ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

Ascelia Pharma company presentation May 2020

Download our fact sheet: Ascelia Pharma factsheet

Lead candidate Mangoral (Phase III) is an MRI imaging drug being developed for detection and localization of liver metastases.

Oncoral (phase II ready) is a novel tablet-based irinotecan formulation, intended for treatment of advanced gastric (stomach) cancer.

• August 20 @ 08:00

  Half-year financial report 2020 (Jan-Jun)

• September 1 @ 08:00 - September 4 @ 17:00

  LSX Nordic congress 2020

• September 2 @ 08:00 - 17:00

  Pareto Securities’ Healthcare conference

• November 5 @ 08:00

  Interim financial report 9M 2020 (Jan-Sep)

• 2021-02-16 @ 08:00

  Full-year financial report 2020 (Jan-Dec)

• 2020-07-31Change in number of shares and votes in Ascelia Pharma AB
• 2020-06-30Ascelia Pharma completes a directed new share issue of 4,697,781 shares, raising approximately SEK 98.7 million
• 2020-06-09Presentation of Ascelia Pharma at ABGSC Life Science Summit Day and Redeye Orphan Drug Day
• 2020-05-20Updated SPARKLE timelines due to Covid-19 impact
• 2020-05-13Interim Financial Report Q1-2020: First patient enrolled in Phase 3 study SPARKLE